

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GREAT POINT PARTNERS LLC (Last) (First) (Middle) 165 MASON STREET 3RD FLOOR (Street) GREENWICH CT 06830 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Foamix Pharmaceuticals Ltd. [FOMX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Former 10% Owner
	3. Date of Earliest Transaction (Month/Day/Year) 09/13/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								4,781,708 ⁽¹⁾	I	Investment Manager ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* GREAT POINT PARTNERS LLC (Last) (First) (Middle) 165 MASON STREET 3RD FLOOR (Street) GREENWICH CT 06830 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person*		
<u>JAY JEFFREY R</u>		
(Last)	(First)	(Middle)
C/O GREAT POINT PARTNERS, LLC		
165 MASON STREET, 3RD FLOOR		
(Street)		
GREENWICH	CT	06830
(City) (State) (Zip)		

1. Name and Address of Reporting Person*		
<u>KROIN DAVID</u>		
(Last)	(First)	(Middle)
C/O GREAT POINT PARTNERS, LLC		
165 MASON STREET, 3RD FLOOR		
(Street)		
GREENWICH	CT	06830
(City) (State) (Zip)		

Explanation of Responses:

1. Consists of 1,400,081 shares owned by Biomedical Value Fund, L.P. ("BVF"), 1,809,973 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 1,395,476 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 176,178 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
2. Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Remarks:

On September 13, 2018, the Issuer conducted an offering of its common stock. As a result of the issuance of such additional shares, the Reporting Persons are no longer the beneficial owners of more than ten percent of any class of the Issuer's securities and are therefore no longer subject to Section 16.

<u>/s/ Dr. Jeffrey R. Jay,</u>	<u>09/14/2018</u>
<u>M.D.Senior</u>	
<u>/s/ Dr. Jeffrey R. Jay, M.D.</u>	<u>09/14/2018</u>
<u>/s/ David Kroin</u>	<u>09/14/2018</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.